1. Home
  2. COSM vs BLRX Comparison

COSM vs BLRX Comparison

Compare COSM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cosmos Health Inc.

COSM

Cosmos Health Inc.

HOLD

Current Price

$0.23

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$2.79

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COSM
BLRX
Founded
2009
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
12.6M
IPO Year
2009
2010

Fundamental Metrics

Financial Performance
Metric
COSM
BLRX
Price
$0.23
$2.79
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
5.4M
9.0K
Earning Date
04-15-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
46.15
N/A
EPS
N/A
N/A
Revenue
$65,271,815.00
N/A
Revenue This Year
$54.08
N/A
Revenue Next Year
$32.66
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.93
N/A
52 Week Low
$0.16
$2.15
52 Week High
$1.32
$4.56

Technical Indicators

Market Signals
Indicator
COSM
BLRX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
COSM
BLRX

About COSM Cosmos Health Inc.

Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: